MTVA Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

3 Analyst Rating

Wall Street analysts forecast MTVA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MTVA is 9.67 USD with a low forecast of 5.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

5.00

Averages

9.67

High

12.00

Current: 0.000

Low

5.00

Averages

9.67

High

12.00

H.C. Wainwright

Andrew Fein

initiated

$12

2025-09-04

Reason

H.C. Wainwright

Andrew Fein

Price Target

$12

2025-09-04

initiated

Reason

H.C. Wainwright analyst Andrew Fein assumed coverage of MetaVia with a Buy rating and $12 price target. The firm says Metavia offers a \"compelling opportunity\" in the metabolic disease space based on its two \"differentiated\" pipeline programs.

Maxim

Jason McCarthy

Buy

downgrade

$6 -> $3

2025-05-19

Reason

Maxim

Jason McCarthy

Price Target

$6 -> $3

2025-05-19

downgrade

Buy

Reason

Maxim analyst Jason McCarthy lowered the firm's price target on MetaVia to $3 from $6 and keeps a Buy rating on the shares. The firm cites the company's Q1 results, cash update, and its recent $10M financing in adjusting its model, though it remains positive on MetaVia's obesity (DA-1726) and MASH (DA-1241) treatment opportunities, the analyst tells investors in a research note.

Valuation Metrics

The current forward P/E ratio for MetaVia Inc (MTVA.O) is -1.54, compared to its 5-year average forward P/E of -0.94. For a more detailed relative valuation and DCF analysis to assess MetaVia Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-0.94

Current PE

-1.54

Overvalued PE

-0.52

Undervalued PE

-1.36

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

Annual

Quarterly

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

MTVA News & Events

Events Timeline

No data

News

9.0

01-05PRnewswire

MetaVia's DA-1726 Clinical Trial Shows Significant Weight Loss of 21.2 lbs

1.0

2025-12-29PRnewswire

MetaVia Inc. Sponsors MASH-TAG 2026 Conference, Focusing on Cardiometabolic Diseases

3.5

2025-12-22Newsfilter

MetaVia Inc. Regains Nasdaq Compliance with Minimum Bid Price Requirement

People Also Watch

Frequently Asked Questions

What is MetaVia Inc (MTVA) stock price today?

The current price of MTVA is 8.155 USD — it has decreased -2.72 % in the last trading day.

What is MetaVia Inc (MTVA)'s business?

MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. It is developing DA-1726 for the treatment of obesity and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and type 2 diabetes. Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide 1, glucagon-dependent insulinotropic polypeptide receptor, and peptide YY.

What is the price predicton of MTVA Stock?

What is MetaVia Inc (MTVA)'s revenue for the last quarter?

MetaVia Inc revenue for the last quarter amounts to -3.48M USD, decreased -44.48 % YoY.

What is MetaVia Inc (MTVA)'s earnings per share (EPS) for the last quarter?

MetaVia Inc. EPS for the last quarter amounts to -2955000.00 USD, decreased -46.74 % YoY.

What changes have occurred in the market's expectations for MetaVia Inc (MTVA)'s fundamentals?

The market is revising No Change the revenue expectations for MetaVia Inc. (MTVA) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -24.18%.

How many employees does MetaVia Inc (MTVA). have?

MetaVia Inc (MTVA) has 9 emplpoyees as of January 10 2026.

What is MetaVia Inc (MTVA) market cap?

Today MTVA has the market capitalization of 18.82M USD.